Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.

Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25. Review.

2.

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.

Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C.

Onco Targets Ther. 2019 Mar 25;12:2159-2170. doi: 10.2147/OTT.S194745. eCollection 2019.

3.

Predictive markers in lung cancer: a few hints for the practicing pathologist.

Barbareschi M, Barberis M, Buttitta F, Doglioni C, Fiorentino M, Fontanini G, Franco R, Marchetti A, Rossi G, Troncone G.

Pathologica. 2018 Mar;110(1):29-38. Review.

PMID:
30259911
4.

Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle.

Marchetti A, Di Lorito A, Buttitta F.

J Thorac Dis. 2017 Dec;9(12):4863-4866. doi: 10.21037/jtd.2017.11.105. No abstract available.

5.

Critical Limb Ischemia: A Practical Up-To-Date Review.

Fabiani I, Calogero E, Pugliese NR, Di Stefano R, Nicastro I, Buttitta F, Nuti M, Violo C, Giannini D, Morgantini A, Conte L, Barletta V, Berchiolli R, Adami D, Ferrari M, Di Bello V.

Angiology. 2018 Jul;69(6):465-474. doi: 10.1177/0003319717739387. Epub 2017 Nov 21. Review.

PMID:
29161885
6.

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.

Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, Volante M, Buttitta F, Guerini-Rocco E, Righi L, D'antuono T, Scagliotti GV, Pinto C, De Rosa G, Papotti M.

J Thorac Oncol. 2017 Nov;12(11):1654-1663. doi: 10.1016/j.jtho.2017.07.031. Epub 2017 Aug 14.

7.

Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report.

Gambale E, Carella C, Amerio P, Buttitta F, Patea RL, Natoli C, De Tursi M.

Int Med Case Rep J. 2017 May 23;10:173-175. doi: 10.2147/IMCRJ.S134944. eCollection 2017.

8.

Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays.

Marchetti A, Pace MV, Di Lorito A, Canarecci S, Felicioni L, D'Antuono T, Liberatore M, Filice G, Guetti L, Mucilli F, Buttitta F.

Lung Cancer. 2016 Sep;99:11-6. doi: 10.1016/j.lungcan.2016.06.005. Epub 2016 Jun 14.

PMID:
27565907
9.

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.

Marchetti A, Di Lorito A, Pace MV, Iezzi M, Felicioni L, D'Antuono T, Filice G, Guetti L, Mucilli F, Buttitta F.

J Thorac Oncol. 2016 Apr;11(4):487-95. doi: 10.1016/j.jtho.2015.12.111. Epub 2016 Feb 22.

10.

Reduction of atherothrombotic burden before stent deployment in non-ST elevation acute coronary syndromes: Reduction of myocardial necrosis achieved with nose-dive manual thrombus aspiration (REMNANT) trial. A volumetric intravascular ultrasound study.

Zimarino M, Angeramo F, Prasad A, Ruggieri B, Malatesta S, Prati F, Buttitta F, De Caterina R.

Catheter Cardiovasc Interv. 2016 Nov;88(5):716-725. doi: 10.1002/ccd.26301. Epub 2015 Nov 3.

PMID:
26527239
11.

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.

Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiari R, Del Grammastro M, Filice G, Ludovini V, Brandes AA, Chella A, Malorgio F, Guglielmi F, De Tursi M, Santoro A, Crinò L, Buttitta F.

J Thorac Oncol. 2015 Oct;10(10):1437-43. doi: 10.1097/JTO.0000000000000643.

12.

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG.

Nat Genet. 2015 Mar;47(3):250-6. doi: 10.1038/ng.3218. Epub 2015 Feb 9.

13.

Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.

Bordi P, Tiseo M, Barbieri F, Bavieri M, Sartori G, Marchetti A, Buttitta F, Bortesi B, Ambrosini-Spaltro A, Gnetti L, Silini EM, Ardizzoni A, Rossi G.

Lung Cancer. 2014 Dec;86(3):324-8. doi: 10.1016/j.lungcan.2014.10.002. Epub 2014 Oct 12.

PMID:
25453846
14.

Identification of microRNAs 758 and 33b as potential modulators of ABCA1 expression in human atherosclerotic plaques.

Mandolini C, Santovito D, Marcantonio P, Buttitta F, Bucci M, Ucchino S, Mezzetti A, Cipollone F.

Nutr Metab Cardiovasc Dis. 2015 Feb;25(2):202-9. doi: 10.1016/j.numecd.2014.09.005. Epub 2014 Oct 5.

PMID:
25445880
15.

Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer.

Gasparini G, Buttitta F, D'Andrea MR, Tumolo S, Buonadonna A, Pavese I, Cordio S, De Tursi M, Mosconi S, Stumbo L, Felicioni L, Marchetti A.

Neoplasia. 2014 Sep;16(9):751-6. doi: 10.1016/j.neo.2014.08.002.

16.

ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme.

Marchetti A, Barberis M, Papotti M, Rossi G, Franco R, Malatesta S, Buttitta F, Ardizzoni A, Crinò L, Gridelli C, Taddei GL, Clemente C, Scagliotti G, Normanno N, Pinto C.

J Thorac Oncol. 2014 Oct;9(10):1470-6. doi: 10.1097/JTO.0000000000000280.

17.

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.

Marchetti A, Del Grammastro M, Felicioni L, Malatesta S, Filice G, Centi I, De Pas T, Santoro A, Chella A, Brandes AA, Venturino P, Cuccurullo F, Crinò L, Buttitta F.

PLoS One. 2014 Aug 19;9(8):e103883. doi: 10.1371/journal.pone.0103883. eCollection 2014.

18.

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, Marchetti A, Crinò L.

Clin Lung Cancer. 2014 Nov;15(6):470-4. doi: 10.1016/j.cllc.2014.06.004. Epub 2014 Jun 24. No abstract available.

PMID:
25087901
19.

Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control.

Santovito D, De Nardis V, Marcantonio P, Mandolini C, Paganelli C, Vitale E, Buttitta F, Bucci M, Mezzetti A, Consoli A, Cipollone F.

J Clin Endocrinol Metab. 2014 Sep;99(9):E1681-5. doi: 10.1210/jc.2013-3843. Epub 2014 Jun 17.

PMID:
24937531
20.

PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.

Cuorvo LV, Verderio P, Ciniselli CM, Girlando S, Decarli N, Leonardi E, Ferro A, Caldara A, Triolo R, Eccher C, Cantaloni C, Mauri F, Seckl M, Volante M, Buttitta F, Marchetti A, Silvia Q, Galligioni E, Palma PD, Barbareschi M.

Virchows Arch. 2014 Jan;464(1):85-93.

PMID:
24233241
21.

microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer.

Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN, Pass HI.

J Thorac Oncol. 2013 Sep;8(9):1156-62. doi: 10.1097/JTO.0b013e318299ac32.

22.

Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing.

Buttitta F, Felicioni L, Del Grammastro M, Filice G, Di Lorito A, Malatesta S, Viola P, Centi I, D'Antuono T, Zappacosta R, Rosini S, Cuccurullo F, Marchetti A.

Clin Cancer Res. 2013 Feb 1;19(3):691-8. doi: 10.1158/1078-0432.CCR-12-1958. Epub 2012 Dec 14.

23.

Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications.

Marchetti A, Del Grammastro M, Filice G, Felicioni L, Rossi G, Graziano P, Sartori G, Leone A, Malatesta S, Iacono M, Guetti L, Viola P, Mucilli F, Cuccurullo F, Buttitta F.

PLoS One. 2012;7(7):e42164. doi: 10.1371/journal.pone.0042164. Epub 2012 Jul 27.

24.

EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.

Milella M, Nuzzo C, Bria E, Sperduti I, Visca P, Buttitta F, Antoniani B, Merola R, Gelibter A, Cuppone F, D'Alicandro V, Ceribelli A, Rinaldi M, Cianciulli A, Felicioni L, Malatesta S, Marchetti A, Mottolese M, Cognetti F.

J Thorac Oncol. 2012 Apr;7(4):672-80. doi: 10.1097/JTO.0b013e31824a8bde.

25.

Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.

Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S, Garagnani L, Sartori G, Calabrese F, Marchetti A, Buttitta F, Felicioni L, Migaldi M, Rea F, Di Chiara F, Mengoli MC, Rossi G.

Ann Oncol. 2012 Sep;23(9):2409-14. doi: 10.1093/annonc/mdr626. Epub 2012 Feb 21.

PMID:
22357254
26.

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, Viola P, Pullara C, Mucilli F, Buttitta F.

J Clin Oncol. 2011 Sep 10;29(26):3574-9. doi: 10.1200/JCO.2011.35.9638. Epub 2011 Aug 8.

PMID:
21825258
27.

A unique microRNA signature associated with plaque instability in humans.

Cipollone F, Felicioni L, Sarzani R, Ucchino S, Spigonardo F, Mandolini C, Malatesta S, Bucci M, Mammarella C, Santovito D, de Lutiis F, Marchetti A, Mezzetti A, Buttitta F.

Stroke. 2011 Sep;42(9):2556-63. doi: 10.1161/STROKEAHA.110.597575. Epub 2011 Aug 4.

PMID:
21817153
28.

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M.

Clin Cancer Res. 2011 Jul 15;17(14):4901-14. doi: 10.1158/1078-0432.CCR-10-3137. Epub 2011 Jun 1.

29.

[Asymptomatic Takayasu's arteritis: an incidental diagnosis].

Grigoratos C, Spontoni P, Coluccia G, Srebot V, Violo C, Buttitta F, Balbarini A.

Recenti Prog Med. 2011 Apr;102(4):162-5. doi: 10.1701/624.7288. Italian.

PMID:
21572493
30.

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, Perrucci B, Carlone D, Gelibter AJ, Ceribelli A, Mezzetti A, Iacobelli S, Cognetti F, Buttitta F.

Neoplasia. 2009 Oct;11(10):1084-92.

31.

The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis.

Paradiso A, Mangia A, Orlando C, Verderio P, Belfiglio M, Marchetti A, Bertario L, Chiappetta G, Gion M, Tonini GP, Podo F, Vocaturo A, Silvestrini R, Romani M, Belloni E, Cavallo D, Ulivi P, Tommasi S, Steffan A, Russo A, Alessio M, Calistri D, Zancan M, Parrela P, Broggini M, Giuseppe A, Buttitta F, Finocchiaro G, Mazzocco K, Veronesi G, Landuzzi L, Benevolo M, Mariani L, De Marco F, Venuti A, Giannelli G, Quaranta M, Trojano V.

Int J Biol Markers. 2009 Jul-Sep;24(3):119-29.

PMID:
19787622
32.

Mutational profile of GNAQQ209 in human tumors.

Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, Scarpa A, Rodolfo M, Knowles M, Frattini M, Marchetti A, Bardelli A.

PLoS One. 2009 Aug 31;4(8):e6833. doi: 10.1371/journal.pone.0006833.

33.

MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway.

Mancini F, Di Conza G, Pellegrino M, Rinaldo C, Prodosmo A, Giglio S, D'Agnano I, Florenzano F, Felicioni L, Buttitta F, Marchetti A, Sacchi A, Pontecorvi A, Soddu S, Moretti F.

EMBO J. 2009 Jul 8;28(13):1926-39. doi: 10.1038/emboj.2009.154. Epub 2009 Jun 11.

34.

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M.

J Clin Oncol. 2009 Apr 1;27(10):1667-74. doi: 10.1200/JCO.2008.19.1635. Epub 2009 Mar 2.

35.

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.

Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A.

Hum Mutat. 2009 Jan;30(1):7-11. doi: 10.1002/humu.20937.

PMID:
19117336
36.

AKT1(E17K) in human solid tumours.

Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, Grammastro MD, Sciarrotta MG, Zanon C, Marchetti A, Bardelli A.

Oncogene. 2008 Sep 18;27(42):5648-50. doi: 10.1038/onc.2008.170. Epub 2008 May 26.

PMID:
18504432
37.

Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung.

Marchetti A, Felicioni L, Pelosi G, Del Grammastro M, Fumagalli C, Sciarrotta M, Malatesta S, Chella A, Barassi F, Mucilli F, Camplese P, D'Antuono T, Sacco R, Buttitta F.

Hum Mutat. 2008 May;29(5):609-16. doi: 10.1002/humu.20707.

PMID:
18293376
38.

Survival prediction of stage I lung adenocarcinomas by expression of 10 genes.

Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, Buttitta F, Felicioni L, Nicassio F, Di Fiore PP.

J Clin Invest. 2007 Nov;117(11):3436-44.

39.

Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.

Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A.

Clin Cancer Res. 2007 Oct 15;13(20):6064-9.

40.

The effects of acute passive smoke exposure on endothelium-dependent brachial artery dilation in healthy individuals.

Giannini D, Leone A, Di Bisceglie D, Nuti M, Strata G, Buttitta F, Masserini L, Balbarini A.

Angiology. 2007 Apr-May;58(2):211-7.

PMID:
17495271
41.

Is transcutaneous oxygen and carbon dioxide monitoring indispensable in short- and long-term therapeutic management of non-reconstructable lower critical limb ischemia?

Melillo E, Nuti M, Pedrinelli R, Buttitta F, Balbarini A.

Minerva Cardioangiol. 2006 Aug;54(4):481-98. English, Italian.

PMID:
17016419
42.

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.

Buttitta F, Barassi F, Fresu G, Felicioni L, Chella A, Paolizzi D, Lattanzio G, Salvatore S, Camplese PP, Rosini S, Iarussi T, Mucilli F, Sacco R, Mezzetti A, Marchetti A.

Int J Cancer. 2006 Dec 1;119(11):2586-91.

43.

[Medical therapy in critical lower limb ischemia when immediate revascularization is not feasible].

Melillo E, Nuti M, Buttitta F, Balbarini A.

G Ital Cardiol (Rome). 2006 May;7(5):317-35. Review. Italian.

PMID:
16752515
44.

Assessing EGFR mutations.

Marchetti A, Felicioni L, Buttitta F.

N Engl J Med. 2006 Feb 2;354(5):526-8; author reply 526-8. No abstract available.

PMID:
16452569
45.

[Prostatic cancer: molecular bases].

Buttitta F.

Pathologica. 2005 Aug;97(4):164-5. Italian. No abstract available.

PMID:
16440630
46.

PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.

Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D, Marchetti A.

J Pathol. 2006 Feb;208(3):350-5.

PMID:
16353168
47.

Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.

Giglio S, Mancini F, Gentiletti F, Sparaco G, Felicioni L, Barassi F, Martella C, Prodosmo A, Iacovelli S, Buttitta F, Farsetti A, Soddu S, Marchetti A, Sacchi A, Pontecorvi A, Moretti F.

Cancer Res. 2005 Nov 1;65(21):9687-94.

48.

Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human.

Cipollone F, Fazia ML, Iezzi A, Cuccurullo C, De Cesare D, Ucchino S, Spigonardo F, Marchetti A, Buttitta F, Paloscia L, Mascellanti M, Cuccurullo F, Mezzetti A.

Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1925-31. Epub 2005 Jul 14.

PMID:
16020747
49.

Int6 expression can predict survival in early-stage non-small cell lung cancer patients.

Buttitta F, Martella C, Barassi F, Felicioni L, Salvatore S, Rosini S, D'Antuono T, Chella A, Mucilli F, Sacco R, Mezzetti A, Cuccurullo F, Callahan R, Marchetti A.

Clin Cancer Res. 2005 May 1;11(9):3198-204.

50.

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F.

J Clin Oncol. 2005 Feb 1;23(4):857-65.

PMID:
15681531

Supplemental Content

Loading ...
Support Center